Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Matosinhos – page 7

691 clinical trials in Matosinhos, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Matosinhos at a glance
691
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

691 trials in Matosinhos

Open in trial search

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Matosinhos

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on Frontotemporal Dementia and various forms of Multiple Sclerosis, including primary progressive and secondary progressive variants. Studies are evaluating novel therapeutic approaches and long-term treatment options.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Epilepsy Interventions

Clinical investigations include assessment of new compounds for refractory focal onset epilepsy and progressive neurological conditions.

02 Respiratory Medicine

Comprehensive studies addressing Pulmonary Fibrosis and chronic respiratory conditions. Research focuses on innovative treatments for chronic rhinosinusitis and progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis
  • Chronic Rhinosinusitis
  • COPD Management

Trials aim to improve lung function and reduce disease progression in various respiratory conditions.

03 Cardiovascular Studies

Advanced research in Heart Failure and stroke prevention, particularly focusing on patients with atrial fibrillation. Studies evaluate new treatment combinations and preventive strategies.

  • Stroke Prevention
  • Heart Failure Management
  • Systemic Embolism Prevention

Research includes comparative studies of new medications for cardiac conditions and prevention strategies.

04 Oncology Research

Targeted studies on Neuroendocrine Cancers, including small cell lung cancer and other specialized cancer types. Research focuses on advanced treatment options for patients with limited therapeutic alternatives.

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
  • Advanced Cancer Therapies

Trials evaluate new therapeutic approaches for patients who have progressed after standard treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.